TPB

Turning Point BrandsD

NYSE / Food Beverage & Tobacco

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$132.50

+59.9% vs current

Most likely

Base case

55%

Probability

Target price

$102.00

+23.1% vs current

B-

Bear case

20%

Probability

Target price

$69.00

-16.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-06

AI commentary

News tone around the May 7 print was constructive because the company delivered strong Modern Oral growth and raised FY2026 outlooks, but the post-print move later cooled and the June 5 anchor sits below the analyst target median. There is no meaningful analyst revision package in the packet, and social/options/employee coverage is incomplete, so this remains a monitored rerating story rather than a de-risked bull case.

RankAlpha Sentiment Codex - 2026-06-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07eventQ1 2026 print reaffirmed the Modern Oral rerating storyMedium impact

The May 7 release and follow-on earnings summary showed consolidated Q1 net sales up 16.8% to $124.3 million, Modern Oral net sales up 133% to $52.0 million, and higher FY2026 Modern Oral and EBITDA outlooks; the market already reacted, but the print still anchors the bull case. [#SEC-8K-2026-05-07][#PR-EARNINGS-2026-05-08]

2026-06-30catalystTariffs, PMTA spending, and Zig-Zag softness remain the main downside risksMedium impact

Q1 still carried PMTA-related costs, Stoker's margin was pressured by tariffs on imported materials, Zig-Zag net sales declined 22% year over year, and SG&A rose sharply with sales and marketing investment, so margin leverage and free cash flow are not yet fully de-risked. [#10-Q-2026-05-08][#PR-EARNINGS-2026-05-08]

2026-12-31catalystModern Oral distribution and manufacturing scale can keep mix shiftingHigh impact

If new chain wins, D2C-to-retail expansion, and Louisville localization continue to improve supply control and unit economics, Modern Oral can keep taking share and support a higher multi-quarter valuation. [#PR-EARNINGS-2026-05-08]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-06 • Updated nightlySource: Internal modelMethodology